Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 10, 2010, Pages 1882-1884

  Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALX 0081; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 1779; CLOPIDOGREL; COLLAGEN; DESMOPRESSIN; DNA; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; GPG 290; HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 82D6A3; MONOCLONAL ANTIBODY AJW200; MONOCLONAL ANTIBODY H6B4; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN ISCHEMIA; CORONARY STENT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; STROKE; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD;

ANIMALS; BRAIN ISCHEMIA; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE; VON WILLEBRAND FACTOR;

EID: 77957711448     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.212316     Document Type: Editorial

References (23)

1. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112:3555-3562.
2. De Meyer SF, Schwarz T, Deckmyn H, Denis CV, Nieswandt B, Stoll G, Vanhoorelbeke K, Kleinschnitz C. Binding of von Willebrand factor to collagen and GPIba, but not to GPIIb/IIIa, contributes to ischemic stroke in mice [epub ahead of print]. Arterioscler Thromb Vasc Biol. 2010; PMID:20616311.
3. Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, Deckmyn H. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113:3600-3603.
4. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330.
5. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
6. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Hematol. 2008;142:515-528.
7. Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol. 2008;8:147-152.
8. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117: 1449-1459.
9. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol. 2002;443:143-149.
10. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, Yoshimoto R. Pharmacokinetics and pharmacody-namics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22:187-192. (Pubitemid 34076252)
11. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116: 2678-2686.
12. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction. Platelets. 2009;20:334-340.
13. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. Inhibition of von Wille-brand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Hemost. 2009;7:1155-1162.
14. Knöbl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49: 2181-2185.
15. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. A randomized pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease [epub ahead of print]. Thromb Hemost. 2010;104:PMID:20589313.
16. Ulrichts H, Schoolmeester A, Hoefman S, Lauwereys M, Casteels P, Stanssens P, Baumeister J, Roodt J, de Jaegere PPT, Holz J. Anti-thrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to current marketed antiplatelet drugs. J Thromb Hemost 2009;(suppl):AS-Th-024.
17. Holz J, Bartunek J, Barbato E, Vercruysse K, Pullan S, Heydrickxs G. ALX-0081 a novel anti-thrombotic: first results of a multiple dose phase I study in patients with stable angina undergoing PCI. J Thromb Hemost. 2009;(suppl):PP-WE-416.
18. Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Desmet J, Deckmyn H. Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Hemost. 2006;96:671-684.
19. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, Deckmyn H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99:3623-3628.
20. Vanhoorelbeke K, Depraetere H, Romijn RA, Huizinga EG, De Maeyer M, Deckmyn H. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J Biol Chem. 2003;278:37815-37821.
21. De Meyer SF, Staelens S, Badenhorst PN, Pieters H, Lamprecht S, Roodt J, Janssens S, Meiring M, Vanhoorelbeke K, Bruwer A, Brown S, Deckmyn H. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor-collagen interaction in baboons. Thromb Hemost. 2007;98:1343-1349.
22. Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, Huang Q. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Hemost. 2007;98:397-405.
23. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351:683-694.